Jordi Mata-Fink, PhD, cofounder of Gate Bioscience, joins Vineeta Agarwala and Ben Portney of a16z Bio + Health.

In this episode, Jordi discusses how he and his cofounders are working to commercialize a novel class of therapeutics, termed 'molecular gates.' His company, Gate, is working to exploit a previously uncharted avenue in cell biology—the secretory translocon—for therapeutic intervention. This approach has the potential to combat diseases otherwise resistant to existing therapeutics.

Jordi also imparts valuable insights on the power of platform-based problem-solving and team building.